Calidi Biotherapeutics reports Q3 net loss of $2.0M; cash increases to $10.1M after business combination

Calidi Biotherapeutics, Inc.

2023-Q3 EPS reported -$1.98

Net loss of $2.0M ($0.14 per share) for Q3 2023 versus $5.4M loss ($0.63 per share) for Q3 2022.
R&D expenses rose to $3.3M from $1.9M; G&A decreased to $4.0M from $5.0M.
Cash and restricted cash of $10.3M as of Sept 30, 2023, versus $0.6M at Dec 31, 2022, reflecting business combination.
First patient dosed by City of Hope in Phase 1 trial of CLD-101 for recurrent high-grade glioma; interim data expected 1H2024.
Appointed Andrew Jackson as CFO and Alan Stewart to Board of Directors.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Calidi Biotherapeutics, Inc. reported third quarter 2023 results: net income $2.0 million, or $0.14 per share, EPS $0.14 per share.

Period: third quarter 2023
Net income: $2.0 million, or $0.14 per share
EPS: $0.14 per share
Result: reported results

Exact text from the filing

The company reported a net loss of $2.0 million, or $0.14 per share, for the three months ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-041223

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.